Business
Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device
ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for its Closed System Transfer Device designed to liquify drugs for patients who cannot swallow solids.\n\nThe Closed System Transfer Device or CSTD combines the act of crushing a solid drug, dissolving in liquid and giving to a patient who cannot swallow for various reasons. The single-use device mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system making the delivery technology both safe for patients and medical professionals, particularly when seeking to liquify or dissolve hazardous drugs.\nFollowing the signing of the exclusive license agreement with RAMBAM, the company plans to develop and file for 510K approval in the United States in the coming months.\nThe licensing of RAMBAM's CSTD device compliments the goal and pipeline of Nutriband Inc., which is to improve safety, comfort, and efficacy for the patient, primarily targeting already approved drugs to improve patient outcomes.\nAbout Nutriband Inc.The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.\nThe Company's website is www.nutriband.com 4P's (Subsidiary) website is www.4PTherapeutics.com. Pocono Pharma's (Subsidiary) website is www.poconopharma.comAny material contained in or derived from any of the company's websites or any other website is not part of this press release.\nAbout Our Forward-Looking StatementsCertain statements contained in this press release, including, without limitation, statements containing the words \"believes,\" \"anticipates,\" \"expects,\" plans and words of similar import, constitute \"forward-looking statements\" within the meani...